Insuficiencia Cardiaca

Insuf Card 2016;11 (3): 115-121

 

Pulmonary arterial hypertension of congenital heart diseases in adults

Impact and results

Registry Data GUTI-GUCH

 

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

 

Received: 6/25/2016

Accepted: 8/15/2016

 

Introduction

 

Adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It’s calculated that 85-90% of these patients with congenital heart disease will reach adulthood. The series of events that follow for these patients include complications, new surgeries and procedures.

It is estimated that 5 to 10% of patients with ACHD develop pulmonary hypertension (PH) in their development, in actuality it’s the most frequent cause for pulmonary arterial hypertension (PAH) after disease of the connective tissue. Its appearance in the patient signifies a much worst prognosis.

The objective of the study was to analyze the epidemiological characteristics clinical and pharmacological treatment in patients with pulmonary arterial hypertension (PAH) and their impact on survival